Next Article in Journal
Sacroiliac Screw Placement with Ease: CT-Guided Pelvic Fracture Osteosynthesis in the Elderly
Previous Article in Journal
Deviating from the Recommended Torque on Set Screws Can Reduce the Stability and Fatigue Life of Pedicle Screw Fixation Devices
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 6
10.3390/medicina58060810
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis

by
Tatsuki Inoue
1,2,
Mana Tsukada
1,*,
Yoshiki Tsunokawa
1,2,
Yoshiko Maeda
2,
Seiya Fukuoka
1,
Takashi Fukagai
2,
Yoshio Ogawa
2 and
Masataka Sunagawa
1
1
Department of Physiology, School of Medicine, Showa University, Tokyo 142-8555, Japan
2
Department of Urology, School of Medicine, Showa University, Tokyo 142-8666, Japan
*
Author to whom correspondence should be addressed.
Medicina 2022, 58(6), 810; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060810
Submission received: 12 May 2022 / Revised: 9 June 2022 / Accepted: 13 June 2022 / Published: 15 June 2022
(This article belongs to the Section Urology & Nephrology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background and Objectives: The Japanese herbal medicine Yokukansan (YKS) has analgesic properties and is used for various pain disorders. The purpose of the present study was to investigate the effects of YKS in Hunner-type interstitial cystitis (HIC) using an experimental rat model of HIC and to explore its antioxidant activity and role as the underlying mechanism of action. Materials and Methods: The antioxidant capacity of YKS was evaluated by determining its hydroxyl radical (·OH) scavenging capacity using electron spin resonance (ESR). Next, the effects of YKS administration were explored using a toll-like receptor-7 agonist-induced rat model of HIC. The von Frey test was performed to assess bladder pain. Three days after HIC induction, the bladder was removed, and the expression of oxidative stress parameters in the bladder wall was investigated (reactive oxygen metabolites (ROMs), ·OH, and 8-hydroxy-2′-deoxyguanosine (8-OhdG)). Results: YKS had a ·OH scavenging capacity according to the ESR study. In the von Frey test, a significant decrease in the withdrawal threshold was observed in the HIC group compared with the control group; however, the decrease was ameliorated by the administration of YKS. Oxidative stress parameters showed increasing tendencies (ROMs test and 8-OHdG) or a significant increase (·OH) in the HIC group compared with the control group; however, the increase was significantly suppressed by the administration of YKS. Conclusions: These findings suggest that YKS is effective against HIC and that its antioxidant activity is involved in the mechanism of action.

1. Introduction

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a nonspecific chronic inflammatory disease of the bladder that causes lower urinary tract symptoms, such as urinary frequency, urinary incontinence, voiding pain, and chronic pelvic pain [1,2]. As in most cases, its etiology is unknown; IC/BPS is considered an idiopathic disease [3]. It is divided into Hunner-type (HIC) and non-Hunner-type IC based on the presence of Hunner lesions, but there is consensus that these should be separated as distinct diseases [4,5]. In Japan, it is divided into IC and BPS based on the presence of Hunner lesions.
There is no established treatment for HIC, and it is designated as an intractable disease in Japan [6]. According to the symptoms, current treatment methods include dietary guidance, medication, and surgical procedure, and commonly used therapeutic agents include analgesic, antidepressant, antiallergic, and immunosuppressive agents [7]. In addition, bladder hydrodistension and bladder instillation treatments using heparin, steroids, or dimethyl sulfoxide (DMSO) were also performed [8,9,10].
In Japan, Kampo formulae are commonly used clinically in addition to Western medicines. Kampo formulae are herbal drugs used in traditional Japanese medicine that consist of several crude drugs, the extracts of which are generally administered. They have been used in many cases for the treatment of lower urinary tract conditions [11,12,13,14,15]. The Kampo formula Yokukansan (YKS) has analgesic properties and is used in various painful conditions [16,17,18,19,20]. It also demonstrated beneficial effects in patients with HIC; however, YKS has not yet been commonly used for the treatment of HIC, and its efficacy and the underlying mechanism of action have not been clarified. Since Kampo formulae generally exert antioxidant activity [21,22], and DMSO, used for bladder instillation treatment [8,9,10], also has an antioxidant effect [23,24], we hypothesized that the antioxidant activity of YKS might be underlying its efficacy in alleviating the symptoms of HIC.
Therefore, the purpose of the present study was to investigate the effects of YKS in HIC using an experimental animal model and to verify its antioxidant activity and its role as the possible underlying mechanism of action.

2. Materials and Methods

2.1. YKS

Dry powdered extracts of YKS (Lot No. 2110054010) used in the present study were supplied by Tsumura and Co. (Tokyo, Japan). The seven herbs (Table 1) were mixed and extracted with purified water at 95.1 °C for 1 h; the soluble extract was separated from the insoluble waste and concentrated by removing water under reduced pressure. The three-dimensional high-performance liquid chromatography profile chart of YKS showing the major chemical compounds was provided by Tsumura and Co. (Figure 1). The details of chemical compounds are shown in Table A1 of Appendix A. Kampo formulae are strictly stipulated by the Japanese pharmacopeia that the extract contains the specified active ingredient in a certain concentration, and its quality is maintained [25].

2.2. Antioxidant Capacity of YKS

Qualitative and quantitative analysis of hydroxyl radical (·OH) generated by the Fenton reaction was performed. In the Fenton reaction, ferrous iron reacts with hydrogen peroxide, which is reduced to generate ·OH. Since ·OH has a short life, it is detected using the electron spin resonance (ESR) spin trapping method. In the present study, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO; LM-2110, LABOTEC Co., Ltd., Tokyo, Japan) was used as a trapping reagent, and ·OH was detected as a DMPO-OH radical.
In detail, after weighing dry powdered YKS (5, 10, 20, and 30 mg), 100 μL of 1 mM FeSO4 was added to each YKS sample and mixed. Ascorbic acid samples (0.67, 1, 2, and 2.5 mg) (012-04802, FUJIFILM Wako Chemicals, Osaka, Japan) were also prepared as comparative samples. An aliquot of water (120 μL) was mixed with 40 μL of each sample preprocessed with FeSO4—20 μL of 89 mM DMPO and 20 μL of 100 mM H2O2 in a plastic cuvette for 1 min. Next, the sample was transferred to a cuvette cell for ESR spectrometry, and the ESR spectrum was recorded on an ESR spectrometer (EMX-micro ESR spectrometer, Bruker BioSpin, Ettlingen, Germany). The measurement conditions for ESR were as follows: field sweep, 3450−3500 G; field modulation frequency, 9.84 GHz; field modulation width, 0.1 mT; sweep time, 30 s; time constant, 0.01 s; microwave frequency, 9.420 GHz; and microwave power, 10 mW. The ESR spectrum of chromium (Cr3+) held in the ESR cavity was used as an internal standard.
Measurements were performed twice for each sample, and the average values were used in the analysis. The ·OH scavenging capacity was shown by the ratio of the radical quantity generated when YKS or ascorbic acid was added ([DMPO-OH]s) to the radical quantity generated without YKS or ascorbic acid ([DMPO-OH]0).

2.3. Animal Investigations

2.3.1. Animals

Animal experiments were performed using 8-week-old female Wistar rats (Nippon Bio-Supp. Center, Tokyo, Japan). Rats were housed three to four per cage (W 24 × L 40 × H 20 cm) under a 12 h light/dark cycle in our animal facility with a controlled environment (temperature 25 ± 2 °C and humidity 55 ± 5%). Food (CLEA Japan, CE-2, Tokyo, Japan) and water were provided ad libitum.
The experiments were performed in accordance with the guidelines of the Committee of Animal Care and Welfare of Showa University. All experimental procedures were approved by the Committee of Animal Care and Welfare of Showa University (certificate number: 02085, date of approval: 1 April 2020). An effort was made to minimize the number of animals used and their suffering.

2.3.2. Groups and Induction of HIC

We used a toll-like receptor-7 (TLR7) agonist-induced rat model of HIC [26,27]. Similar to human HIC, this model exhibits frequent voiding and bladder pain-like behavior, and inflammatory cell infiltration, edema, and capillary congestion are observed in the suburothelial bladder layer.
Twenty-one rats were randomly divided into three groups, as follows: control, HIC, and YKS-treated HIC (YKS+HIC) groups. Since this model is an acute model and the symptoms do not last long [26], we decided to examine the effect of YKS by preadministration. YKS was mixed with powdered rodent chow (CE-2: CLEA Japan) at a concentration of 3% and fed to the YKS+HIC group for 7 days prior to the induction of cystitis. This dose was chosen based on the effective doses of YKS in our previous study [28,29]. Rats that were not treated with YKS were fed powdered chow only.
All rats were lightly anesthetized using intraperitoneally (i.p.) administered pentobarbital sodium (30 mg/kg; Somnopentyl, Kyoritsu Seiyaku Co., Tokyo, Japan). A polyethylene catheter (PE-10; Becton Dickinson, Franklin Lakes, NJ, USA) was transurethrally inserted into the bladder, and urine was drained. Next, 200 μL of 4.5 mM loxoribine (AG-CR1-3584, Adipogen Corp., San Diego, CA, USA), a selective TLR7 agonist, was instilled slowly in rats in the HIC and YKS+HIC groups. In the control group, distilled water was instilled instead of loxoribine. The catheter was kept in place for 60 min, after which the instilled liquid was drained.

2.3.3. Von Frey Test

The von Frey test was performed to assess bladder pain at baseline, prior to HIC induction (day 1), and on days 2 and 3. Studies assessed rodent responses to von Frey filaments of varying diameters to determine the thresholds for noxious stimuli for the body part of interest [30,31]. The rats were placed in test cages with a wire mesh bottom for 30 min before the test. The surface of the lower abdomen close to the bladder was pushed, and the minimum value that caused withdrawal behavior was determined as the threshold.

2.3.4. Measurement of Oxidative Stress

On day 3, the bladders of all rats were removed under deep anesthesia with pentobarbital sodium (50 mg/kg i.p.; Somnopentyl). A part of each bladder was plunged into 5 volumes (v/w) of a protein extraction reagent (N-PER, Thermo Scientific, Rockford, IL, USA) and then homogenized twice at 1500 rpm for 120 s using a tissue homogenizer (BMS-M10N21, Bio Medical Science Inc., Tokyo, Japan). The homogenate was centrifuged at 2000× g for 10 min, and the supernatant was collected. The total protein concentrations in the samples were determined using the Pierce™ BCA Protein Assay Kit (23227; Thermo Scientific, Waltham, MA, USA). The concentrations of all samples were standardized based on the amount of protein. Samples were subsequently stored at −80 °C until the analysis. The remaining part of each bladder was 4% formalin-fixed, embedded, and frozen in Tissue-Tek optimum cutting temperature (OTC) compound (Tissue-Tek OCT, Sakura Finetek, Torrance, CA, US) and stored at −80 °C until use.
The following oxidative stress markers were evaluated:
  • OH—detected using the ESR spin trapping method, as described above. An aliquot of water (120 μL) was mixed with 20 μL of each bladder sample—20 μL of 1.0 M DMPO, 20 μL of 10 mM FeSO4, and 20 μL of 100 mM H2O2 in a plastic cuvette for 1 min. The subsequent measurements are as described above;
  • Reactive oxygen metabolites (ROMs)—oxidative stress level was measured using the diacron reactive oxygen metabolites (d-ROMs) test (d-ROMs Kit; Diacron International S.r.l., Grosseto, Italy) [32]. ROMs of a biological sample, primarily hydroperoxides, are able to generate alkoxyl and peroxyl radicals, according to Fenton’s reaction. These radicals oxidize an alkyl-substituted aromatic amine (N,N-dietylparaphenylendiamine), thus producing a pink-colored derivative that is photometrically quantified at 505 nm using the free radical analytical system (FREE carpe diem; Diacron International S.r.l.) [33]. The concentration of ROMs is directly correlated with the color intensity and is expressed as Carratelli Units (1 CARR U = 0.08 mg hydrogen peroxide/dL) [34];
  • 8-hydroxy-2′-deoxyguanosine (8-OHdG)—8-OHdG produced by oxidative damage to DNA by reactive oxygen species (ROS) was detected using enzyme-linked immunosorbent assay and fluorescent immunostaining methods. The concentrations of 8-OHdG in the homogenate samples were measured using a kit (KOG-HS10E, Japan Institute for the Control of Aging, Fukuoka, Japan). The assay sensitivity was <0.125 ng/mL, and the intra- and inter-assay CVs were 2.1% and 7.1%, respectively. All measurement procedures were conducted according to the manufacturer’s instructions.
The frozen bladders in the OCT compound were cut into 25 µm sections using a cryostat (CM1860; Leica Biosystems, Nussloch, Germany). Sections were incubated overnight at 4 °C with rabbit anti-8-OHdG antibody (1:200, bs-1278R, Bioss, Woburn, MA, USA). Sections were then incubated for 2 h with fluorophore-tagged secondary antibody (donkey anti-rabbit Alexa Fluor 555, 1:1000, #A31572, Thermo Fisher Scientific, Waltham, MA, USA). Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole, 1:1000, Thermo Fisher Scientific). Samples were imaged using a confocal laser scanning fluorescence microscope (FV1000D, Olympus, Tokyo, Japan).

2.4. Statistical Analysis

All experimental data are expressed as medians (25% and 75% percentiles). All data analyses were performed using statistical software (SPSS 15.0J for Windows; SPSS Japan, Tokyo, Japan). Because the data had a skewed distribution, differences among the three groups were analyzed using the Kruskal–Wallis test. If there were significant differences in the Kruskal–Wallis test, the Bonferroni post hoc test was used to analyze the differences between each group. Statistical significance was set at p < 0.05.

3. Results

3.1. OH Scavenging Capacity of YKS

Compared to the same amount of ascorbic acid, a well-known antioxidant [35], YKS demonstrated a lower ·OH scavenging capacity (Figure 2a). Since YKS is a mixture and each has a different digestion and absorption process, we considered that these would be administered to humans and compared them at the appropriate daily dose. The daily dose of YKS for adults is 3.25 g [36], and the recommended dose of ascorbic acid for adults by the National Institutes of Health (office of dietary supplements) is 90 mg for men and 75 mg for women [37]. The daily dose of YKS is more than 30 times higher. With reference to these doses, ascorbic acid (0.67 mg) and YKS (20 mg), and ascorbic acid (1 mg) and YKS (30 mg) were compared. YKS shows higher (· OH) scavenging capacity (Figure 2b).

3.2. Animal Investigations

3.2.1. Von Frey Test

Withdrawal thresholds were measured at baseline (day 1) and on days 2 and 3. Since the baseline values varied across animals, the values obtained on day 2 (Figure 3a) and day 3 (Figure 3b) are shown by the rate of change in relation to a baseline value of 1. On both days 2 and 3, a significant decrease in the threshold value was observed in the HIC group compared with the control group; however, the decrease was suppressed by the administration of YKS (day 2, p = 0.023; day 3, p = 0.072).

3.2.2. Oxidative Stress Parameters

Representative stress parameters were measured to examine the changes in oxidative stress levels in the bladder wall (Table 2). The specific ESR signal (1:2:2:1) of the DMPO-OH adduct was detected (Figure 4a). The values were then expressed and converted to moles (Figure 4b). ·OH showed a significant increase in the HIC group compared with the control group; however, the increase was significantly suppressed by the administration of YKS.
ROMs and 8-OHdG also showed increasing tendencies in the HIC group; however, the increases were significantly suppressed in the YKS+HIC group (Figure 5a,b). In particular, the 8-OHdG expression in the HIC group increased in the bladder epithelium (Figure 5c–h).

4. Discussion

In the present study, the administration of YKS inhibited bladder pain-like behavior and suppressed the increase in expression of oxidative stress markers in the bladder wall in a rat model of HIC.
Kampo formulae were reported to have certain antioxidant activity [21,22]. In this study, the ·OH scavenging capacity of YKS was verified by comparing it with that of ascorbic acid, which is a well-known antioxidant agent. The result showed that ascorbic acid exhibited higher ·OH scavenging capacity than YKS. However, YKS exhibited higher ·OH scavenging capacity when adjusted for the daily dose. We will also compare these antioxidant effects in vivo. YKS contains many ingredients, and all its main ingredients, such as liquiritin [38], liquiritin apioside [39], and ferulic acid [40], have antioxidant capacity. In order to determine which ingredient played a central role in its antioxidant activity, we will further investigate the individual ·OH scavenging capacity of YKS ingredients.
Numerous animal studies suggested the involvement of ROS and the effect of antioxidants in IC. ROS played an important role in the cyclophosphamide (CP)-induced cystitis model, and antioxidants such as melatonin, alpha-tocopherol, ascorbic acid, and daidzin were found to ameliorate bladder damage induced by CP [41,42,43]. Furthermore, in CP- or ifosfamide-induced cystitis animal models, the metabolite acrolein caused bladder inflammation, which was prevented by ROS scavengers or antioxidants [43,44,45]. In clinical practice, bladder instillation treatment is performed using DMSO, which is a hydroxyl radical scavenger [8,9,10]. Therefore, we hypothesized that ROS plays an important role in the pathology of IC and that the antioxidant effect of YKS may contribute to IC suppression.
In the present study, to verify the effect of YKS on HIC, we used the TLR7 agonist-induced HIC animal model established by Ichihara et al. [26]. They found an increase in the TLR7 mRNA expression in the bladder of patients with HIC and established the HIC model by applying a TLR7 agonist, loxorbine. This model of rats showed bladder pain-like behavior, such as licking or biting the skin of the lower abdomen [26,27]. Bladder pain was assessed by the von Frey test, which is frequently used in cystitis model rats [30,31]. The withdrawal threshold in the HIC group was significantly lower than that in the control group following HIC induction; however, the decline was suppressed in the YKS+HIC group, which suggested the potential efficacy of YKS in alleviating HIC symptoms.
Next, we measured three oxidative stress parameters in the bladder wall. ·OH is the most reactive oxygen metabolite of various free radicals, and 8-OHdG is produced by oxidative damage of DNA induced by ·OH. The d-ROMs test evaluates the degree of oxidative stress by measuring the total peroxidative substances generated by various ROS, including ·OH. The level of ·OH increased significantly, and its reaction products 8-OHdG and ROMs also showed increasing tendencies; however, the increase was significantly suppressed by the administration of YKS. As mentioned above, ROS may play an important role in IC development [41,42,43,44,45,46], and the production of ·OH, which is one of ROS, increased in the TLR7 agonist-induced HIC model as well. Furthermore, the premedication with YKS was able to suppress ROS production.
TLR7 is expressed in immune cells, such as B cells, macrophages, and dendritic cells, recognizes single-stranded RNA of viruses and bacteria, and is involved in infection defense by inducing the production of interferon and inflammatory cytokines [47,48]. However, it was also reported to be involved in the development of autoimmune diseases, such as systemic lupus erythematosus, by erroneously reacting with own RNA [49]. In neutrophils and B cells, TLR7 agonists activate NADPH oxidase, increasing ROS production [50,51]. Influenza A virus infection increases oxidative stress by upregulating the expression of TLR7 [52]. Liquiritin [53], liquiritin apioside [54], and ferulic acid [55] included in YKS are reported to suppress the activity of NADPH oxidase. It is possible that these ingredients were involved in the YKS antioxidant activity exhibited in this study, and in the future, we will investigate the effect of YKS on TLR7 and NADPH oxidase in this experimental system.
To our knowledge, there has never been a study in which YKS was applied to HIC model animals. Our first goal of the present study was to investigate whether YKS had any effect on HIC, and the study was conducted without positive controls. Since the efficacy was suggested in the present study, we plan to further investigate the mechanism of action and examine whether it is useful in comparison with other therapeutic agents by setting positive controls. There are some more limitations to the present study. We only evaluated pain-like behavior and did not evaluate urination or the inflammatory findings of the bladder wall; thus, these analyses will be performed in the next study. It is necessary to clarify whether the inhibition of ·OH production is involved in the mechanism of action underlying the analgesic effect of YKS. Furthermore, the currently widely used chemical-induced IC model animals, including the HIC model we used, show only the symptoms of acute cystitis and cannot be evaluated for chronic cystitis. In the future, we will also use and verify a model with chronic symptoms [30].

5. Conclusions

In this study, we explored the effects of YKS in a rat model of HIC and found that it was effective in suppressing HIC symptoms. Furthermore, our findings indicated that the antioxidant activity of YKS is involved in the mechanism of action underlying its analgesic effect. These findings suggest that YKS may suppress the onset and/or exacerbation of HIC.

Author Contributions

Conceptualization and methodology, T.I., M.T. and M.S.; investigation, T.I., M.T., Y.T., S.F. and M.S.; resources, T.I. and Y.T.; data curation and formal analysis, M.T. and M.S.; writing—original draft preparation, T.I.; writing—review and editing, all authors; visualization, M.S.; supervision and project administration, Y.M., T.F. and Y.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The experiments were performed in accordance with the guidelines of the Committee of Animal Care and Welfare of Showa University. All experimental procedures were approved by the Committee of Animal Care and Welfare of Showa University (certificate number: 02085, date of approval: 1 April 2020).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available from the corresponding author on reasonable request.

Acknowledgments

All authors are grateful to Tsumura and Co. for generously providing YKS.

Conflicts of Interest

M.S. received a research grant from Tsumura and Co. (Tokyo, Japan). The remaining authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

8-OHdG, 3. 8-hydroxy-2′-deoxyguanosine; BPS, bladder pain syndrome; CP, cyclophosphamide; DAPI, 4′,6-diamidino-2-phenylindole; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide; DMSO, dimethyl sulfoxide; d-ROMs, diacron reactive oxygen metabolites; ESR; electron spin resonance; HIC, Hunner-type interstitial cystitis; IC, interstitial cystitis; i.p., intraperitoneally; ·OH, hydroxyl radical; ROMs, reactive oxygen metabolites; ROS, reactive oxygen species; TLR7, toll-like receptor-7; YKS, Yokukansan; YKS+HIC, Yokukansan-treated HIC.

Appendix A

Table
Table A1. Chemical compounds identified in the three-dimensional high-performance liquid chromatography profile chart of Yokukansan (YKS).
Table A1. Chemical compounds identified in the three-dimensional high-performance liquid chromatography profile chart of Yokukansan (YKS).
Component
Galenicals of YKS 		Chemical CompoundsStructureChemical Class
Atractylodes Lancea4E,6E,12E-tetradecatriene-8,10-diyne-1,3,14-triol Medicina 58 00810 i001polyacetylene
12-isovaleroyl-2E,8E,10E-triene-4,6-diyne-1,14-diol Medicina 58 00810 i002polyacetylene
14-isovaleroyl-2E,8E,10E-triene-4,6-diyne-1,12-diol Medicina 58 00810 i003polyacetylene
atractylodin Medicina 58 00810 i004polyacetylene
atractylodinol Medicina 58 00810 i005polyacetylene
acetylatractylodinol Medicina 58 00810 i006polyacetylene
Cnidium Rhizomeferulic acid Medicina 58 00810 i007phenolic acid
Ligustilide * Medicina 58 00810 i008Butenolide
Japanese Angelica
xanthotoxin Medicina 58 00810 i009coumarin
Uncaria Thorngeissoschizine methyl ether Medicina 58 00810 i010indole alkaloid
hirsuteine Medicina 58 00810 i011indole alkaloid
hirsutine Medicina 58 00810 i012indole alkaloid
Bupleurumsaikosaponin b1 Medicina 58 00810 i013triterpene saponin
saikosaponin b2 Medicina 58 00810 i014triterpene saponin
Glycyrrhizaliquiritin Medicina 58 00810 i015flavonoid
liquiritin apioside Medicina 58 00810 i016flavonoid
isoliquiritin Medicina 58 00810 i017flavonoid
isoliquiritin apioside Medicina 58 00810 i018flavonoid
glycyroside Medicina 58 00810 i019flavonoid
glycyrrhizin Medicina 58 00810 i020triterpene glycoside
liquiritigenin Medicina 58 00810 i021flavonoid
formonetin-7-O-glucoside Medicina 58 00810 i022flavonoid
glycycoumarin Medicina 58 00810 i023coumarin
formononetin Medicina 58 00810 i024flavonoid
The chemical compounds identified in the three-dimensional high-performance liquid chromatography profile chart (Figure 1), their structures, and chemical classes are shown. (*) Ligustilide is included in Cnidium Rhizome and Japanese Angelica.

References

  1. Homma, Y.; Akiyama, Y.; Tomoe, H.; Furuta, A.; Ueda, T.; Maeda, D.; Lin, A.T.; Kuo, H.C.; Lee, M.H.; Oh, S.J.; et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2020, 27, 578–589. [Google Scholar] [CrossRef] [PubMed]
  2. Hanno, P.M.; Erickson, D.; Moldwin, R.; Faraday, M.M. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J. Urol. 2015, 193, 1545–1553. [Google Scholar] [CrossRef] [PubMed]
  3. Akiyama, Y. Biomarkers in interstitial cystitis/bladder pain syndrome with and without Hunner lesion: A review and future perspectives. Diagnostics 2021, 11, 2238. [Google Scholar] [CrossRef] [PubMed]
  4. Fall, M.; Nordling, J.; Cervigni, M.; Dinis Oliveira, P.; Fariello, J.; Hanno, P.; Kåbjörn-Gustafsson, C.; Logadottir, Y.; Meijlink, J.; Mishra, N.; et al. Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: An ESSIC working group report. Scand. J. Urol. 2020, 54, 91–98. [Google Scholar] [CrossRef] [PubMed]
  5. Lai, H.H.; Pickersgill, N.A.; Vetter, J.M. Hunner lesion phenotype in interstitial cystitis/bladder pain syndrome: A systematic review and meta-analysis. J. Urol. 2020, 204, 518–523. [Google Scholar] [CrossRef]
  6. Akiyama, Y.; Hanno, P. Phenotyping of interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2019, 26, 17–19. [Google Scholar] [CrossRef] [Green Version]
  7. van de Merwe, J.P.; Nordling, J.; Bouchelouche, P.; Bouchelouche, K.; Cervigni, M.; Daha, L.K.; Elneil, S.; Fall, M.; Hohlbrugger, G.; Irwin, P.; et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur. Urol. 2008, 53, 60–67. [Google Scholar] [CrossRef]
  8. Rawls, W.F.; Cox, L.; Rovner, E.S. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review. Neurourol. Urodyn. 2017, 36, 1677–1684. [Google Scholar] [CrossRef]
  9. Colemeadow, J.; Sahai, A.; Malde, S. Clinical management of bladder pain syndrome/interstitial cystitis: A review on current recommendations and emerging treatment options. Res. Rep. Urol. 2020, 12, 331–343. [Google Scholar] [CrossRef]
  10. Kollerup Madsen, B.; Hilscher, M.; Zetner, D.; Rosenberg, J. Adverse reactions of dimethyl sulfoxide in humans: A systematic review. F1000Research 2018, 7, 1746. [Google Scholar] [CrossRef]
  11. Kawashima, N.; Deveaux, T.E.; Yoshida, N.; Matsumoto, K.; Kato, K. Choreito, a formula from Japanese traditional medicine (Kampo medicine), for massive hemorrhagic cystitis and clot retention in a pediatric patient with refractory acute lymphoblastic leukemia. Phytomedicine 2012, 19, 1143–1146. [Google Scholar] [CrossRef] [PubMed]
  12. Sekiguchi, Y.; Azekoshi, Y.; Kawazi, K.; Nagasaki, N.; Nagai, Y.; Kaneko, Y.; Yoshida, M.; Kubota, Y. Four interstitial cystitis/chronic pelvic syndrome (IC/CPPS) cases improved by Kampo medicine. Kampo Med. 2014, 65, 268–272, (In Japanese, English Abstract). [Google Scholar] [CrossRef] [Green Version]
  13. Kawashima, N.; Ito, Y.; Sekiya, Y.; Narita, A.; Okuno, Y.; Muramatsu, H.; Irie, M.; Hama, A.; Takahashi, Y.; Kojima, S. Choreito formula for BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2015, 21, 319–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Takahashi, S.; Takei, M.; Nishizawa, O.; Yamaguchi, O.; Kato, K.; Gotoh, M.; Yoshimura, Y.; Takeyama, M.; Ozawa, H.; Shimada, M. Clinical guideline for female lower urinary tract symptoms. Low Urin. Tract. Symptoms 2016, 8, 5–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Lee, C.L.; Shin, H.K.; Lee, J.Y.; Kwon, O.; Seo, C.S.; Kim, A.R.; Seo, B.N.; Yang, S.W.; Song, K.H.; Lim, J.S. Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double blinded, randomized, pilot clinical trial. Int. J. Urol. 2022, 29, 503–509. [Google Scholar] [CrossRef]
  16. Sunagawa, M.; Takayama, Y.; Kato, M.; Tanaka, M.; Fukuoka, S.; Okumo, T.; Tsukada, M.; Yamaguchi, K. Kampo formulae for the treatment of neuropathic pain∼ especially the mechanism of action of yokukansan∼. Front. Mol. Neurosci. 2021, 14, 705023. [Google Scholar] [CrossRef]
  17. Yamaguchi, K. Traditional Japanese herbal medicines for treatment of odontopathy. Front. Pharmacol. 2015, 6, 176. [Google Scholar] [CrossRef] [Green Version]
  18. Tanaka, M.; Tanaka, T.; Takamatsu, M.; Shibue, C.; Imao, Y.; Ando, T.; Baba, H.; Kamiya, Y. Effects of the Kampo medicine Yokukansan for perioperative anxiety and postoperative pain in women undergoing breast surgery: A randomized, controlled trial. PLoS ONE 2021, 16, e0260524. [Google Scholar] [CrossRef]
  19. Suzuki, Y.; Mitsuhata, H.; Yuzurihara, M.; Kase, Y. Antiallodynic effect of herbal medicine yokukansan on peripheral neuropathy in rats with chronic constriction injury. Evid. Based Complement. Alternat. Med. 2012, 2012, 953459. [Google Scholar] [CrossRef] [Green Version]
  20. Ebisawa, S.; Andoh, T.; Shimada, Y.; Kuraishi, Y. Yokukansan improves mechanical allodynia through the regulation of interleukin-6 expression in the spinal cord in mice with neuropathic pain. Evid. Based Complement. Alternat. Med. 2015, 2015, 870687. [Google Scholar] [CrossRef] [Green Version]
  21. Nishimura, K.; Osawa, T.; Watanabe, K. Evaluation of oxygen radical absorbance capacity in kampo medicine. Evid. Based Complement Alternat. Med. 2011, 2011, 812163. [Google Scholar] [CrossRef] [PubMed]
  22. Hirayama, A.; Oowada, S.; Ito, H.; Matsui, H.; Ueda, A.; Aoyagi, K. Clinical significance of redox effects of Kampo formulae, a traditional Japanese herbal medicine: Comprehensive estimation of multiple antioxidative activities. J. Clin. Biochem. Nutr. 2018, 62, 39–48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Sandström, B.E. Effects of quin2 acetoxymethyl ester on H2O2-induced DNA single-strand breakage in mammalian cells: H2O2-concentration-dependent inhibition of damage and additive protective effect with the hydroxyl-radical scavenger dimethyl sulphoxide. Biochem. J. 1995, 305, 181–185. [Google Scholar] [CrossRef]
  24. Schins, R.P.; Knaapen, A.M.; Cakmak, G.D.; Shi, T.; Weishaupt, C.; Borm, P.J. Oxidant-induced DNA damage by quartz in alveolar epithelial cells. Mutat. Res. 2002, 517, 77–86. [Google Scholar] [CrossRef]
  25. Japanese Ministry of Health, Labour and Welfare. The Japanese Pharmacopoeia, 18th ed.; Japanese Ministry of Health, Labour and Welfare: Tokyo, Japan, 2021; pp. 2173–2175. Available online: https://www.mhlw.go.jp/content/11120000/000912390.pdf (accessed on 11 May 2022).
  26. Ichihara, K.; Aizawa, N.; Akiyama, Y.; Kamei, J.; Masumori, N.; Andersson, K.-E.; Homma, Y.; Igawa, Y. Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. Pain 2017, 158, 1538–1545. [Google Scholar] [CrossRef]
  27. Tabata, H.; Sasaki, M.; Kataoka-Sasaki, Y.; Shinkai, N.; Ichihara, K.; Masumori, N.; Kocsis, J.D.; Honmou, O. Possible role of intravenous administration of mesenchymal stem cells to alleviate interstitial cystitis/bladder pain syndrome in a toll-like receptor-7 agonist-induced experimental animal model in rat. BMC Urol. 2021, 21, 156. [Google Scholar] [CrossRef]
  28. Akanuma, Y.; Kato, M.; Takayama, Y.; Ikemoto, H.; Adachi, N.; Ohashi, Y.; Yogi, W.; Okumo, T.; Tsukada, M.; Sunagawa, M. Analgesic efficacy of a combination of fentanyl and a Japanese herbal medicine “Yokukansan” in rats with acute inflammatory pain. Medicines 2020, 7, 75. [Google Scholar] [CrossRef]
  29. Takemoto, M.; Sunagawa, M.; Okada, M.; Ikemoto, H.; Suga, H.; Katayama, A.; Otake, H.; Hisamitsu, T. Yokukansan, a Kampo medicine, prevents the development of morphine tolerance through the inhibition of spinal glial cell activation in rats. Integr. Med. Res. 2016, 5, 41–47. [Google Scholar] [CrossRef] [Green Version]
  30. Ackerman, A.L.; Jellison, F.C.; Lee, U.J.; Bradesi, S.; Rodríguez, L.V. The Glt1 glutamate receptor mediates the establishment and perpetuation of chronic visceral pain in an animal model of stress-induced bladder hyperalgesia. Am. J. Physiol. Renal. Physiol. 2016, 310, F628–F636. [Google Scholar] [CrossRef] [Green Version]
  31. Ding, H.; Chen, J.; Su, M.; Lin, Z.; Zhan, H.; Yang, F.; Li, W.; Xie, J.; Huang, Y.; Liu, X.; et al. BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis. J. Neuroinflamm. 2020, 17, 19. [Google Scholar] [CrossRef] [Green Version]
  32. Faienza, M.F.; Francavilla, R.; Goffredo, R.; Ventura, A.; Marzano, F.; Panzarino, G.; Marinelli, G.; Cavallo, L.; Di Bitonto, G. Oxidative stress in obesity and metabolic syndrome in children and adolescents. Horm. Res. Paediatr. 2012, 78, 158–164. [Google Scholar] [CrossRef] [PubMed]
  33. Alberti, A.; Bolognini, L.; Macciantelli, D.; Caratelli, M. The radical cation of N,N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 2000, 26, 253–267. [Google Scholar] [CrossRef]
  34. Trotti, R.; Carratelli, M.; Barbieri, M. Performance and clinical application of a new, fast method for the detection of hydroperoxides in serum. Panminerva Med. 2002, 44, 37–40. [Google Scholar] [PubMed]
  35. Mashino, T.; Takigawa, Y.; Saito, N.; Wong, L.Q.; Mochizuki, M. Antioxidant activity and xanthine oxidase inhibition activity of reductic acid: Ascorbic acid analogue. Bioorg. Med. Chem. Lett. 2000, 10, 2783–2785. [Google Scholar] [CrossRef]
  36. Yokukansan Extract Granules for Ethical Use. Available online: https://www.tsumura.co.jp/english/products/pi/JPR_T054.pdf (accessed on 11 May 2022).
  37. Fact Sheet for Health Professionals Vitamin C. Available online: https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/#h6 (accessed on 11 May 2022).
  38. Li, X.Q.; Cai, L.M.; Liu, J.; Ma, Y.L.; Kong, Y.H.; Li, H.; Jiang, M. Liquiritin suppresses UVB-induced skin injury through prevention of inflammation, oxidative stress and apoptosis through the TLR4/MyD88/NF-κB and MAPK/caspase signaling pathways. Int. J. Mol. Med. 2018, 42, 1445–1459. [Google Scholar] [CrossRef] [Green Version]
  39. Guan, Y.; Li, F.F.; Hong, L.; Yan, X.F.; Tan, G.L.; He, J.S.; Dong, X.W.; Bao, M.J.; Xie, Q.M. Protective effects of liquiritin apioside on cigarette smoke-induced lung epithelial cell injury. Fundam. Clin. Pharmacol. 2012, 26, 473–483. [Google Scholar] [CrossRef]
  40. Scott, B.C.; Butler, J.; Halliwell, B.; Aruoma, O.I. Evaluation of the antioxidant actions of ferulic acid and catechins. Free Radic. Res. Commun. 1993, 19, 241–253. [Google Scholar] [CrossRef]
  41. Sadir, S.; Deveci, S.; Korkmaz, A.; Oter, S. Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats. Cell Biochem. Funct. 2007, 25, 521–526. [Google Scholar] [CrossRef]
  42. Farshid, A.A.; Tamaddonfard, E.; Ranjbar, S. Oral administration of vitamin C and histidine attenuate cyclophosphamide-induced hemorrhagic cystitis in rats. Indian J. Pharmacol. 2013, 45, 126–129. [Google Scholar] [CrossRef] [Green Version]
  43. Wu, K.-C.; Lin, W.-Y.; Sung, Y.-T.; Wu, W.-Y.; Cheng, Y.-H.; Chen, T.-S.; Chiang, B.-J.; Chien, C.-T. Glycine tomentella hayata extract and its ingredient daidzin ameliorate cyclophosphamide-induced hemorrhagic cystitis and oxidative stress through the action of antioxidation, anti-fibrosis, and anti-inflammation. Chin. J. Physiol. 2019, 62, 188–195. [Google Scholar] [CrossRef]
  44. Yildirim, I.; Korkmaz, A.; Oter, S.; Ozcan, A.; Oztas, E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother. Pharmacol. 2004, 54, 469–473. [Google Scholar] [CrossRef] [PubMed]
  45. Song, J.; Liu, L.; Li, L.; Liu, J.; Song, E.; Song, Y. Protective effects of lipoic acid and mesna on cyclophosphamide-induced haemorrhagic cystitis in mice. Cell. Biochem. Funct. 2014, 32, 125–132. [Google Scholar] [CrossRef] [PubMed]
  46. Hiramoto, S.; Tsubota, M.; Yamaguchi, K.; Okazaki, K.; Sakaegi, A.; Toriyama, Y.; Tanaka, J.; Sekiguchi, F.; Ishikura, H.; Wake, H.; et al. Cystitis-related bladder pain involves ATP-dependent HMGB1 release from macrophages and its downstream H(2)S/Ca(v)3.2 signaling in mice. Cells 2020, 9, 1748. [Google Scholar] [CrossRef] [PubMed]
  47. Medzhitov, R.; Janeway, C., Jr. The toll receptor family and microbial recognition. Trends Microbiol. 2000, 8, 452–456. [Google Scholar] [CrossRef]
  48. Lund, J.M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N.C.; Gale, N.W.; Iwasaki, A.; Flavell, R.A. Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2004, 101, 5598–5603. [Google Scholar] [CrossRef] [Green Version]
  49. Jenks, S.A.; Cashman, K.S.; Zumaquero, E.; Marigorta, U.M.; Patel, A.V.; Wang, X.; Tomar, D.; Woodruff, M.C.; Simon, Z.; Bugrovsky, R.; et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity 2018, 49, 725–739.e726. [Google Scholar] [CrossRef] [Green Version]
  50. Hayashi, F.; Means, T.K.; Luster, A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102, 2660–2669. [Google Scholar] [CrossRef]
  51. McLetchie, S.; Volpp, B.D.; Dinauer, M.C.; Blum, J.S. Hyper-responsive toll-like receptor 7 and 9 activation in NADPH oxidase-deficient B lymphoblasts. Immunology 2015, 146, 595–606. [Google Scholar] [CrossRef]
  52. To, E.; Broughton, B.R.; Hendricks, K.S.; Vlahos, R.; Selemidis, S. Influenza A virus and TLR7 activation potentiate NOX2 oxidase-dependent ROS production in macrophages. Free Radic. Res. 2014, 48, 940–947. [Google Scholar] [CrossRef]
  53. Mou, S.Q.; Zhou, Z.Y.; Feng, H.; Zhang, N.; Lin, Z.; Aiyasiding, X.; Li, W.J.; Ding, W.; Liao, H.-H.; Bian, Z.Y. Liquiritin attenuates lipopolysaccharides-induced cardiomyocyte injury via an AMP-activated protein kinase-dependent signaling pathway. Front. Pharmacol. 2021, 12, 1118. [Google Scholar] [CrossRef]
  54. Wei, W.; Gao, X.; Zhao, L.; Zhuang, J.; Jiao, Y.; Xu, F. Liquiritin apioside attenuates laryngeal chemoreflex but not mechanoreflex in rat pups. Am. J. Physiol. Lung Cell Mol. Physiol. 2020, 318, L89–L97. [Google Scholar] [CrossRef] [PubMed]
  55. Cao, Y.J.; Zhang, Y.M.; Qi, J.P.; Liu, R.; Zhang, H.; He, L.C. Ferulic acid inhibits H2O2-induced oxidative stress and inflammation in rat vascular smooth muscle cells via inhibition of the NADPH oxidase and NF-κB pathway. Int. Immunopharmacol. 2015, 28, 1018–1025. [Google Scholar] [CrossRef] [PubMed]
Medicina 58 00810 g001 550
Figure 1. Three-dimensional high-performance liquid chromatography (3D-HPLC) profile chart of the major chemical compounds in Yokukansan (YKS).
Figure 1. Three-dimensional high-performance liquid chromatography (3D-HPLC) profile chart of the major chemical compounds in Yokukansan (YKS).
Medicina 58 00810 g001
Medicina 58 00810 g002 550
Figure 2. Hydroxyl radical (·OH) scavenging capacity. The ratio of the radical quantity generated when YKS or ascorbic acid was added ([DMPO-OH]t) to the radical quantity generated without YKS or ascorbic ([DMPO-OH]0). (a) Both showed higher ·OH scavenging capacity in a dose-dependent manner, with ascorbic acid higher. (b) YKS exhibited higher ·OH scavenging capacity when adjusted for the daily dose and compared. YKS, Yokukansan; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide.
Figure 2. Hydroxyl radical (·OH) scavenging capacity. The ratio of the radical quantity generated when YKS or ascorbic acid was added ([DMPO-OH]t) to the radical quantity generated without YKS or ascorbic ([DMPO-OH]0). (a) Both showed higher ·OH scavenging capacity in a dose-dependent manner, with ascorbic acid higher. (b) YKS exhibited higher ·OH scavenging capacity when adjusted for the daily dose and compared. YKS, Yokukansan; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide.
Medicina 58 00810 g002
Medicina 58 00810 g003 550
Figure 3. Von Frey Test. The values obtained on day 2 (a) and day 3 (b) are shown by the rate of change in relation to a baseline value of 1. Horizontal lines within boxes denote median values, and x marks denote the mean values. * Significant difference (p < 0.05) (Kruskal–Wallis test with post hoc test and Bonferroni correction). HIC, Hunner-type interstitial cystitis; YKS, Yokukansan.
Figure 3. Von Frey Test. The values obtained on day 2 (a) and day 3 (b) are shown by the rate of change in relation to a baseline value of 1. Horizontal lines within boxes denote median values, and x marks denote the mean values. * Significant difference (p < 0.05) (Kruskal–Wallis test with post hoc test and Bonferroni correction). HIC, Hunner-type interstitial cystitis; YKS, Yokukansan.
Medicina 58 00810 g003
Medicina 58 00810 g004 550
Figure 4. DMPO-OH radical. (a) DMPO-OH signals detected by ESR. (b) the intensity of the DMPO-OH signal. Horizontal lines within boxes denote median values, and × marks denote the mean values. ·OH significantly increased in the HIC group compared with the control group; however, the increase was significantly suppressed by the administration of YKS. * Significant difference (p < 0.05) (Kruskal–Wallis test with the post hoc test and Bonferroni correction). HIC, Hunner type interstitial cystitis; YKS, Yokukansan; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide; ·OH; Hydroxyl radical.
Figure 4. DMPO-OH radical. (a) DMPO-OH signals detected by ESR. (b) the intensity of the DMPO-OH signal. Horizontal lines within boxes denote median values, and × marks denote the mean values. ·OH significantly increased in the HIC group compared with the control group; however, the increase was significantly suppressed by the administration of YKS. * Significant difference (p < 0.05) (Kruskal–Wallis test with the post hoc test and Bonferroni correction). HIC, Hunner type interstitial cystitis; YKS, Yokukansan; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide; ·OH; Hydroxyl radical.
Medicina 58 00810 g004
Medicina 58 00810 g005 550
Figure 5. Oxidative Stress Parameters. (a) d-ROMs test; (b) 8-OHdG. Horizontal lines within boxes denote median values, and x marks denote the mean values. * Significant difference (p < 0.05) (Kruskal–Wallis test with the post hoc test and Bonferroni correction). (c–h) Immunofluorescent staining of 8-OHdG in the bladder. The upper row (c–e) includes only 8-OHdG, and the lower row (f–h) includes 8-OHdG and nuclei. Red, 8-OHdG; blue, DAPI (nuclei). The white scale bar is 200 μm. HIC, Hunner type interstitial cystitis; YKS, Yokukansan; d-ROMs, diacron reactive oxygen metabolites; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; DAPI, 4′,6-diamidino-2-phenylindole.
Figure 5. Oxidative Stress Parameters. (a) d-ROMs test; (b) 8-OHdG. Horizontal lines within boxes denote median values, and x marks denote the mean values. * Significant difference (p < 0.05) (Kruskal–Wallis test with the post hoc test and Bonferroni correction). (c–h) Immunofluorescent staining of 8-OHdG in the bladder. The upper row (c–e) includes only 8-OHdG, and the lower row (f–h) includes 8-OHdG and nuclei. Red, 8-OHdG; blue, DAPI (nuclei). The white scale bar is 200 μm. HIC, Hunner type interstitial cystitis; YKS, Yokukansan; d-ROMs, diacron reactive oxygen metabolites; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; DAPI, 4′,6-diamidino-2-phenylindole.
Medicina 58 00810 g005
Table
Table 1. The component galenicals of Yokukansan (YKS).
Table 1. The component galenicals of Yokukansan (YKS).
Official Name (Upper Row)
English Name (Lower Row)		Botanical FamilyAmount
Rhizome of Atractylodes japonica Koidz. ex Kitam.
Atractylodes Lancea		Compositae4.0 g
Strain of Pinus densiflora Siebold and Zucc.
Poria		Polyporaceae4.0 g
Rhizome of Cnidium officinale Makino
Cnidium Rhizome		Umbelliferae3.0 g
Hook-bearing stems of Uncaria rhynchophylla (Miq.) Miq.
Uncaria Thorn		Rubiaceae3.0 g
Root of Angelica acutiloba (Siebold and Zucc.) Kitag.
Japanese Angelica		Umbelliferae3.0 g
Root of Bupleurum falcatum L.
Bupleurum		Umbelliferae2.0 g
Root of Glycyrrhiza uralensis Fisch.
Glycyrrhiza		Laguminosae1.5 g
Weights indicate the daily dose, and these are mixed and extracted with 600 mL of purified water (at 95.1 °C).
Table
Table 2. Oxidative Stress Parameters.
Table 2. Oxidative Stress Parameters.
Control (n = 7)HIC (n = 7)YKS+HIC (n = 7)Kruskal–Wallis Test
(p-Value)
DMPO-OH radical
(μM)		0.76 (0.67, 1.04)1.11 (1.10, 1.15)1.04 (0.75, 1.04)0.018 *
d-ROMs
(U.CARR)		364.15 (333.50, 395.93)533.31 (444.64, 579.40)314.80 (247.77, 343.79)0.019 *
8-OhdG
(pg/mL)		8.38 (7.71, 9.04)10.06 (9.70, 11.47)6.74 (6.08, 8.40)0.011 *
All values are expressed as median (25% and 75% percentiles). * p < 0.05 (Kruskal–Wallis test). HIC, Hunner type interstitial cystitis; YKS, Yokukansan; d-ROMs, diacron reactive oxygen metabolites; DMPO, 5,5-dimethyl-1-pyrroline-N-oxide; ·OH; Hydroxyl radical; 8-OHdG, 8-hydroxy-2′-deoxyguanosine.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Inoue, T.; Tsukada, M.; Tsunokawa, Y.; Maeda, Y.; Fukuoka, S.; Fukagai, T.; Ogawa, Y.; Sunagawa, M. The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis. Medicina 2022, 58, 810. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060810

AMA Style

Inoue T, Tsukada M, Tsunokawa Y, Maeda Y, Fukuoka S, Fukagai T, Ogawa Y, Sunagawa M. The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis. Medicina. 2022; 58(6):810. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060810

Chicago/Turabian Style

Inoue, Tatsuki, Mana Tsukada, Yoshiki Tsunokawa, Yoshiko Maeda, Seiya Fukuoka, Takashi Fukagai, Yoshio Ogawa, and Masataka Sunagawa. 2022. "The Japanese Herbal Medicine Yokukansan Exerted Antioxidant and Analgesic Effects in an Experimental Rat Model of Hunner-Type Interstitial Cystitis" Medicina 58, no. 6: 810. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060810

Article Metrics

Back to TopTop